logo-loader
Acasti Pharma Inc.

Acasti Pharma granted allowance for patents in 3 more countries for drug candidate Capre

Acasti Pharma (NASDAQ: ACST-CVE:ACST) Co-Founder and Chief Operating Officer Pierre Lemieux joined Steve Darling from Proactive Investors Vancouver to bring news Acasti received 3 new patents for their flagship drug candidate CaPre.

Lemieux talks about what this means for the company going forward and where in the pipeline CaPre is and what trials will happen this year.

Quick facts: Acasti Pharma Inc.

Price: $2.63

Market: TSX-V
Market Cap: $223.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc. named herein, including the promotion by the Company of Acasti Pharma Inc. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Acasti Pharma gets new Chinese patent that paves the way for its heart...

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) Co-Founder and COO Pierre Lemieux tells Proactive Investors it was awarded a second patent in China covering its flagship drug candidate CaPre, an omega-3 phospholipid. Lemieux says currently in China there is no approved drug like CaPre, where...

on 06/26/2019

2 min read